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Infection  with  the  bacterium  Clostridium  difﬁcile  causes  symptoms  ranging  from  mild  to  severe  diarrhoea
with  life-threatening  complications  and  remains  a signiﬁcant  burden  to  healthcare  systems  throughout
the  developed  world.  Two  potent  cytotoxins,  TcdA  and  TcdB  are  the  prime  mediators  of  the  syndrome
and  rapid  neutralisation  of  these  would  afford  signiﬁcant  beneﬁts  in  disease  management.  In  the  present
study,  a  broad  range  of  non-toxic,  recombinant  fragments  derived  from  TcdA  and  TcdB  were  designed  for
soluble  expression  in  E. coli and  assessed  for their  capacity  to generate  a potent  toxin-neutralising  immune
response  as  assessed  by  cell-based  assays.  Signiﬁcant  differences  between  the  efﬁcacies  of isolated  TcdA
and  TcdB  regions  with  respect  to  inducing  a  neutralising  immune  response  were  observed.  While  the
C-terminal  repeat  regions  played  the  principal  role  in  generating  neutralising  antibodies  to  TcdA,  in  the
case  of  TcdB,  the  central  region  domains  dominated  the  neutralising  immune  response.  For  both  TcdA
and  TcdB,  fragments  which  comprised  domains  from  both  the  central  and  C-terminal  repeat  region  ofoxins the  toxins  were  found  to  induce  the  most  potent  neutralising  immune  responses.  Generated  antibodies
neutralised  toxins  produced  by  a  range  of  C.  difﬁcile  isolates  including  ribotype  027  and  078  strains.
Passive  immunisation  of  hamsters  with  a  combination  of  antibodies  to  TcdA  and  TcdB  fragments  afforded
complete  protection  from  severe  CDI  induced  by  a  challenge  of  bacterial  spores.  The results  of  the study
are  discussed  with  respect  to the  development  of a  cost  effective  immunotherapeutic  approach  for  the
 infec
n Copmanagement  of  C.  difﬁcile
Crow
. Introduction
The Gram positive, anaerobic, spore-forming bacterium Clostrid-
um difﬁcile continues to be a signiﬁcant problem within healthcare
acilities [1–3] with an estimated global ﬁnancial burden of over $12
illion. CDI is caused by ingested spores and is usually preceded
y the use of antibiotics which perturb the normal gut ﬂora. The
acterium colonises the digestive tract and produces potent cyto-
oxins which damage the gut epithelium and cause its characteristic
ymptoms [4,5]. These range from mild, self-limiting diarrhoea to
ometimes life-threatening pseudomembranous colitis and toxic
egacolon [6].
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A 19.6 kb region (PaLoc) of the chromosome of C. difﬁcile
encodes its two principal virulence factors, toxins A (TcdA) and B
(TcdB) [7]. Structurally, TcdA and TcdB are organised as complex,
multi-domain proteins (see Fig. 1) which deﬁne its multi-step
action [8]. Sequence variations in the 19.6 kb region (PaLoc) of the
chromosome, which encodes TcdA and TcdB have been identiﬁed
and these variants, termed toxinotypes, result in sequence differ-
ences between the toxins [9,10].
Current antibiotics, while successful in treating the majority
of CDI cases, are less effective at managing recurrent or severe
CDI [11]. As a consequence, several alternative therapies are
under development [12]. With respect to therapeutic strategies
directed at TcdA and TcdB, a considerable evidence base suggests
that antibody-mediated neutralisation of these toxins affords pro-
tection against CDI [13,14]. These include passive immunisation
studies [15–20] with antibodies to TcdA and TcdB and also vaccines
Open access under CC BY-NC-ND license.designed to evoke a toxin-neutralising immune response to these
toxins [21]. Recombinant vaccine candidates based on polypeptide
fragments representing the C-terminal repeat regions of TcdA and
TcdB have been the focus of a number of studies [22–28].
-ND license.
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SFig. 1. Diagrammatic representation of the TcdA and TcdB regions and expr
Previously, we described the administration of ovine antibodies,
hich potently neutralise TcdA and TcdB, as a potential therapeutic
ption for the treatment of severe CDI [18]. In the current study, we
escribe recombinant fragments derived from the C. difﬁcile toxins
hich can underpin the large-scale production of such therapeutic
ntibodies. Toxin regions critical to the generation of neutralising
ntibodies were also identiﬁed.
.  Materials and methods
.1.  C. difﬁcile strains and puriﬁcation of toxins
C. difﬁcile VPI 10463, CCUG 20309 were from the ATCC. C. difﬁcile
ibotype 027 (NCTC 13366) was a gift from the Anaerobe Refer-
nce Laboratory, Cardiff and C. difﬁcile ribotype 078 (clinical isolate)
as obtained via the C. difﬁcile Ribotyping Network (Southampton).
hese were toxinotyped and maintained as previously described
9,18]. TcdA and TcdB were puriﬁed from C. difﬁcile strains by a
odiﬁcation [18] of a previously described protocol [29].
.2.  Expression and puriﬁcation of recombinant fragments
TcdA and TcdB gene constructs optimised for E. coli expres-
ion were synthesised (Entelechon GmbH) (supplemental Fig. S1)
nd incorporated into the pET28a vector system. E. coli BL21(DE3)
nd BL21 Star (DE3) (Invitrogen) were used as expression hosts
or recombinant toxin fragments. Protein expression was per-
ormed in Phytone Peptone Terriﬁc Broth (PPTB) supplemented
ith kanamycin (50–100 g/ml). E. coli BL21(DE3) containing
xpression constructs were grown in PPTB supplemented with
anamycin in a 3.0 l fermenter (Applikon Biotechnology) and
xpression induced by autoinduction at 25 ◦C or 1 mM isopropyl-
eta-d-thiogalactopyranoside for 16 h at 16 ◦C.
Supplementary material related to this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.vaccine.
013.11.099.
Cell paste (40 g) was  resuspended in 400 ml  of 50 mM  Tris-HCl
H 8.0 buffer containing 500 mM NaCl, 4 mM EDTA, sonicated on
ce (5× 1 min) and the lysate centrifuged (25,000 × g, 20 min) before
eing dialysed against 50 mM Tris–HCl pH 8.0 buffer containing
00 mM  NaCl at 4 ◦C. The dialysed material was made up to 20 mM
midazole using high imidazole buffer (50 mM  Tris–HCl pH 8.0,
00 mM  NaCl, 500 mM imidazole) and applied to a GE Chelating
epharose (nickel) column (100 ml,  ∅ 50 mm).  After washing with recombinant constructs. Numbers correspond to the amino acid sequence.
50  mM  Tris–HCl pH 8.0 buffer containing 500 mM  NaCl, 20 mM
imidazole, bound material was eluted with a 10-column volume
gradient to 100% of the high imidazole buffer. Thrombin cleavage
was carried out in 20 mM Tris–HCl pH 8.4 containing 150 mM NaCl,
2.5 mM  CaCl2 overnight at 20 ◦C using restriction grade thrombin
(Novagen) added at 1 U/mg protein; HRV 3C (Novagen) cleavage
was performed in 50 mM Tris–HCl pH 7.5 buffer with 500 mM NaCl,
2.5 mM  dithiothreitol for 20 h at 4 ◦C using a protease:protein ratio
of 1:200 (wt/wt). Cleaved fragments were dialysed against 50 mM
Tris–HCl pH 7.5 buffer containing 500 mM  NaCl and 20 mM imid-
azole at 4 ◦C and applied (5 ml/min) to a GE Chelating Sepharose
Ni column (100 ml,  ∅ 50 mm)  and the toxin fragment eluted in
the ﬂow through. Proteomic analyses (GeLC–MS/MS) using in-gel
tryptic digestion of constructs were conducted at the Centre for
Proteomic Research, Southampton University [30].
2.3.  Production of ovine antisera and antibodies
Antigens were used to immunise groups of 3 sheep using Fre-
und’s adjuvant as described [18]. For formaldehyde treatment,
antigens in HEPES buffer (50 mM,  pH 7.4) containing 500 mM NaCl
at 0.5–1 mg/ml, were made 0.2% (v/v) with formaldehyde and incu-
bated at 37 ◦C for 24 h and then stored at 4 ◦C. Immunisations were
carried out every 28 days and blood samples taken 14 days after
each immunisation. Once adequate antibody levels were achieved,
larger volumes of blood were taken and the IgG puriﬁed as previ-
ously described [18]. ELISA on serum and puriﬁed IgG (detection
limit, 5–10 ng toxin-speciﬁc IgG/ml) was  conducted by the method
described previously [18].
2.4. Toxin neutralisation assay
A cell-based neutralisation assay using Vero cells was performed
as described previously [18,29]. Cells were assessed by microscopy
for rounding and the highest serum/IgG dilution providing com-
plete protection from the cytotoxic activity of TcdA/B was  recorded
as the neutralisation titre. Antibody toxin neutralisation titres were
also estimated by colorimetric assays based on cell staining with
crystal violet [31]. These assays were performed as described above
using ﬁnal concentrations of TcdA and TcdB in antibody mixtures
of 50 ng/ml and 2 ng/ml respectively. After overnight incubation,
cells were washed gently with 200 l of Dulbecco’s PBS (Sigma)
and ﬁxed with 70 l ice-cold ethanol for 2 min. The ethanol was
then removed and 70 l crystal violet (1%, w/v, in ethanol; Pro-Lab)
702 M. Maynard-Smith et al. / Vaccine 32 (2014) 700– 705
F d TcdB constructs as depicted in Fig. 1. (B) Western blots for key fragments using either
o ntibody was used at a dilution of 1/30,000. (C) SDS-PAGE of a typical IgG preparation in
t y a caprylic acid precipitation method as described [18].
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Fig. 3. Antibody-mediated neutralisation of TcdA and TcdB as measured by the Vero
cell ED50 assay. The capacity of various dilutions of antiserum to TxB2 () and TxB4
()  to prevent the cytotoxic effects of puriﬁed TcdB (2 ng/ml) was assessed using
crystal violet staining to measure cell viability [31]. Neutralisation by TxA2 () and
TxA4 () antiserum was assessed using TcdA at 50 ng/ml. Each antiserum was  a pool
obtained from the immunisation of 3 sheep.ig. 2. Characterisation of recombinant antigens. (A) SDS-PAGE of puriﬁed TcdA an
vine antibody raised against TcdA for TxA4 or to TcdB for TxB4 and TxBcen. Each a
he  presence (Ab+) and absence (Ab−) of dithiothreitol (20 mM).  IgG was puriﬁed b
dded to the ﬁxed cells for 30 min  at 22 ◦C. Plates were washed care-
ully in water to remove excess dye, dried at 37 ◦C and then 200 l of
0% (v/v) ethanol added. Plates were incubated in a shaker incuba-
or (37 ◦C; 300 rpm) for 2 h then read at 492 nm.  ED50 values were
erived from the resulting toxin neutralisation curves using 4 or
-pl nonlinear regression models (SigmaPlot 12.0).
.5.  Animal model for C. difﬁcile infection
The Syrian hamster model was performed as described previ-
usly using groups of 10 animals [30]. All hamsters were weighed
nd administered clindamycin (2 mg  in 0.2 ml  sterile H2O) by the
rogastric route on Day 0. On Day 2, test animals were challenged
orogastrically) with between 102 and 103 colony forming units
f C. difﬁcile spores in 0.2 ml  DMEM.  Animals were weighed daily
nd monitored 6 times/day for 15 days for disease symptoms (diar-
hoea, weight loss, lethargy and tender abdomen) [19,32]. Survival
urves were analysed by log rank tests (non-parametric distribu-
ion analysis, right censoring). For passive immunisation, ovine IgG
as puriﬁed from antisera generated using TxA4 and TxB4 frag-
ents. Doses (0.5–2 ml)  were administered at various times by the
ntraperitoneal route (see Fig. 4).
. Results
.1. Expression, puriﬁcation and assessment of recombinant TcdB
onstructs
The  panel of TcdB-derived fragments is summarised in Fig. 1.
onstruct TxB5 contained the mutation Cys700 → Ser to reduce
ubstantially the activity of the cysteine protease (CP) domain [33].
ith the exception of antigen TxB2, levels of total protein expres-
ion and levels of soluble expression were low without the addition
f an N-terminal fusion protein. Several fusion protein candidates
ere screened and thioredoxin and NusA were found to promote
he highest levels of soluble expression. Details of the design of anti-
en constructs are provided as supplemental data (Fig. S1). Puriﬁed
ragments were analysed by SDS-PAGE (Fig. 2) and immunoblot-
ing. For each construct, the principal protein band reacted strongly
ith antibodies raised to TcdB [18] (data not shown). Proteomic
nalysis of TxB4 by GeLC–MS/MS using in-gel tryptic digestion con-
rmed its identity and presence of >98% of the predicted construct
equence.End points in Vero-cell assays used to assess the levels of
oxin-neutralising antibodies to fragments were determined by
oth microscopy (complete cell protection as the endpoint) and as
n ED50 in which cell integrity was assessed using crystal violetstaining (Fig. 3 and Table 1). While there was  a generally good
correlation between the two  methods used to determine toxin-
neutralising titres in the cell assay, there was little correlation
between these and titres obtained by ELISA. For the latter, <25-
fold variation in titres was observed for the various fragment
sera compared to a >1000 fold difference in the serum neutral-
ising titres. This suggests that neutralising antibodies represent
a variable sub-set of the total toxin speciﬁc antibodies. With the
exception of TxB5, toxin-neutralising titres obtained from animal
sera immunised with native fragments were low. Mild treatment
with formaldehyde signiﬁcantly enhanced toxin neutralising titres
of all fragments with improvements of >100-fold for TxB3 and
TxB4 constructs. For the formaldehyde-treated fragments, inclu-
sion of the central toxin domains markedly increased neutralising
titres compared to TxB2 which consisted of TcdB repeat regions
only. Highest toxin-neutralising titres were obtained with fragment
TxB4 which elicited titres >100-fold that obtained with TxB2. Of
the central domain-containing fragments, TxB4 was  also expressed
in highest yields (approximately 30 mg  puriﬁed antigen per litre)
making it the preferred antigen for generating antibodies to TcdB.
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Table 1
Ovine antibody response to TcdB-derived recombinant antigens.
Antigen ELISA titre Neutralising titre (visual) Neutralising titre ED50
1 2 Mean
Native
TxB2 2 × 104 <10 nda nda nd
TxB3  1 × 105 40 29 ± 3 20 ± 9 25
TxB4  7 × 104 80 32 ± 3 32 ± 3 32
TxB5  5 × 104 640 1196 ± 118 996 ± 158 1096
HCHO-treated (0.2%, v/v)
TxB2  2 × 105 80 41 ± 11 59 ± 13 45
TxB3  5 × 105 5120 7495 ± 1418 9984 ± 2209 8740
TxB4  2 × 105 10,240 23,364 ± 3363 21,309 ± 1620 22,337
TxB5  5 × 104 5120 12,673 ± 1878 14,682 ± 1587 13,678
TxB(cen) 1 × 105 5120 7946 ± 1027 8225 ± 418 8086
For each antigen, 5 doses of 100 g were given monthly to each of 3 sheep and the serum analysed at 18 weeks. ELISA titres, derived from 14-week samples, represent serum
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Dilutions (pool from 3 animals) which gave a signal of 0.5 A450 above background 
etermined by light microscopy and represented the dilution of antiserum that w
ata represent the mean of duplicate determinations. For the crystal violet ED50 as
a Neutralising titres were too low to achieve 50% neutralisation in the assay.
.2. Expression, puriﬁcation and assessment of recombinant TcdA
onstructs
A  panel of recombinant TcdA fragments was expressed and
uriﬁed in a similar manner to that described for the TcdB frag-
ents above (Figs. 1 and S1). In toxin neutralising assays for
everal of the constructs, and notably TxA2, the microscopy-based
ssay end point (100% cell protection) was poorly deﬁned with
 low level of cell death occurring over several dilutions within
he assay. This resulted in a poorer correlation between the neu-
ralising titres derived by the two methods, with the ED50 values
rguably providing a better relative measure of toxin-neutralising
ctivity (Table 2 and Fig. 3). Limited treatment of antigens with
ormaldehyde signiﬁcantly enhanced the neutralising titre elicited
y TxA4, but the effects were less marked than those observed for
he TcdB-derived constructs. The highest toxin neutralising titres
ere obtained with formaldehyde-treated TxA4. Yields of this frag-
ent were lower than that for corresponding TcdB fragment with
ields of 18–20 mg/l puriﬁed fragment obtained. Proteomic anal-
sis of TxA4 by GeLC–MS/MS revealed that an impurity band of
pproximately 70 kDa was a breakdown product of TxA4 repre-
enting the N-terminus of the fragment.
.3. Contribution of the regions of TcdA and TcdB to toxin
eutralisation
Comparison of the data within Tables 1 and 2 with respect
o the ED50 values derived for formaldehyde-treated fragments
eveals signiﬁcant differences with respect to the principal toxin
omains contributing to the toxin-neutralising immune response.
ith respect to neutralisation of TcdB, serum raised against a cen-
ral domain fragment (residues 767–1852; TxBcen) had >150-fold
oxin-neutralising activity compared to the C-terminal fragment,
able 2
vine antibody response to TcdA-derived recombinant antigens.
Antigen ELISA titre Neutralising titre (visual) 
Native
TxA2 2 × 105 640 
TxA4  5 × 105 1280 
HCHO-treated (0.2%, v/v)
TxA2  2 × 105 1280 
TxA4  7 × 105 15,360 
TxA4(tr)  3 × 105 5120 
TxAcen  2 × 105 640 
eterminations were as described in Table 1 with the exception that TcdA was maintainee the mean of duplicate determinations. Visual neutralising titres (units/ml) were
 to completely protect Vero cells from a ﬁxed concentration of TcdB at 0.5 ng/ml.
dB was used at a ﬁxed concentration of TcdB at 2 ng/ml.
TxB2.  That these fragments displayed similar antibody ELISA titres
(approx. 105) against TcdB suggests that this difference is not
due to a poor immune response against the latter fragment. In
contrast, comparison of the toxin-neutralising immune response
elicited by similar fragments derived from TcdA, showed that the
C-terminal fragment, TxA2 had approximately 6-fold increase in
toxin-neutralising activity compared to a central domain fragment
(residues 543–1850; TxAcen). These data indicate signiﬁcant dif-
ferences in the key domains that contribute to a toxin-neutralising
immune response between TcdA and TcdB: the C-terminal region
playing the dominant role in the case of TcdA as opposed to the
central region domains in the case of TcdB.
3.4. Cross-neutralisation of TcdA and TcdB toxinotypes
Neutralising efﬁcacy was  assessed against TcdA and TcdB pro-
duced by key epidemic ribotype 027 and 078 C. difﬁcile strains,
which produce toxinotype 3 and 5 toxins, respectively [10] and
TcdB (toxinotype 10) produced by a TcdA-negative, ribotype 036
strain [34] (Table 3). Antibodies raised against TxA4 were broadly
neutralising with little or no loss of efﬁcacy against toxinotype
3 and 5 toxins. A greater variation in cross-neutralising efﬁcacy
was observed with antibodies raised to TxB4. While a reduction
of <3-fold was  observed against TcdB toxinotypes 3 and 5, a more
marked reduction in neutralising potency was  observed against a
toxinotype 10 TcdB.
3.5.  Protection from CDI by passive immunisationFor passive immunisation studies, the high-toxin producing C.
difﬁcile strain, VPI 10463 was used. After perturbation of the nor-
mal gut ﬂora using clindamycin, passively immunised and control
group animals were challenged with C. difﬁcile spores [18]. In
Neutralising titre ED50
1 2 Mean
21,619 ± 418 16,793 ± 25 19,206
13,232 ± 982 14,010 ± 421 13,621
13,233 ± 384 12,292 ± 614 12,763
28,826 ± 988 32,148 ± 981 30,487
8879 ± 395 8271 ± 246 8575
2472 ± 199 2096 ± 222 2284
d at a ﬁxed concentration of 50 ng/ml in both cell-based assays.
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Table  3
Cross-neutralisation of toxinotypes of TcdA and TcdB.
Immunising antigen Assay toxinotype Neutralising potency ED50
(g/ml IgG)
1 2 Mean
TxA4 TcdA (0) 1.6 ± 0.06 1.5 ± 0.07 1.5
TxA4 TcdA (3) 1.7  ± 0.23 1.4 ± 0.10 1.5
TxA4 TcdA (5) 1.7 ± 0.04 1.7 ± 0.14 1.7
TxB4 TcdB (0) 1.8 ± 0.13 1.5 ± 0.34 1.6
TxB4 TcdB (3) 1.9 ± 0.36 2.0 ± 0.29 2.0
TxB4 TcdB (5) 4.1 ± 0.43 4.0 ± 1.01 4.0
TxB4 TcdB (10) 9.4 ± 2.13 13.7 ± 0.55 11.6
TxBcen TcdB (0) 2.5  ± 0.22 2.1 ± 0.20 2.3
TxBcen TcdB (3) 7.9  ± 0.64 7.5 ± 1.20 7.7
TxBcen TcdB (5) 7.7 ± 0.73 8.1 ± 0.71 7.9
TxBcen TcdB (10) 7.2 ± 0.67 9.0 ± 0.75 8.1
Antibodies to TxA4 and TxB4 antigens (toxinotype 0 sequences) were assessed for
their capacity to neutralise other TcdA and TcdB toxinotypes. Neutralising potencies
are expressed in g/ml IgG required for 50% neutralisation of either TcdA or TcdB at
the concentrations deﬁned below. Thus, lower values represent higher neutralising
efﬁcacy.  Puriﬁed TcdA toxinotypes (0, 3 and 5) were each titrated in the cell assay
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cnd  used at ﬁxed concentration of 32× the minimum toxin concentration, which
auses  cell death in a 24 h incubation period. Puriﬁed TcdB toxinotypes (0, 3, 5 and
0) were used at 16× the minimum lethal concentration.
nimals immunised with a mixture of antibodies raised against
ntigens TxA4 and TxB4, statistically signiﬁcant protection from
DI (p < 0.001) was obtained with survival of 80% of the animals
n the lower antibody doses. At the highest antibody dose, 100% of
he animals were protected from severe CDI at 15 days post chal-
enge; 30% of the animals in this group showed transient diarrhoea
or 1–2 days. Animals which received either no antibody or non-
peciﬁc ovine IgG, all succumbed to severe CDI within 3 days post
hallenge (Fig. 4). Protective efﬁcacy was similar to that observed
reviously using antibodies produced using the full-length toxoids
f TcdA and TcdB [18]..  Discussion
Infection with C. difﬁcile remains a problem within healthcare
ystems of the developed world [35] and additional therapeutic
ig. 4. Protection from CDI by passive immunisation with ovine anti-toxin A/B.
raph  shows survival post challenge with C. difﬁcile VPI 10463 spores in the hamster
odel. Animals (10 per group) were administered (2 ml,  i.p.) with 3 doses of IgG pro-
uced using TxA4 and TxB4 and which consisted () 50 mg  IgG containing 1 × 104
nits anti A, 2 × 104 units anti B; () 25 mg  IgG containing 5 × 103 units anti A, 1 × 104
nits anti B; () 8.3 mg IgG containing 1.7 × 103 units anti A, 3.3 × 103 units anti
.  Toxin neutralising units were determined by the cell-based assay (microscopy-
ased  endpoint) as described in Table 1. A control group () received no antibody.
omparison  of survival curves by log rank analysis showed ,  and , p < 0.001
ompared  to the control group ().ine 32 (2014) 700– 705
options are needed [36]. Previously, we described development
of an immunotherapeutic for CDI based on the administration of
polyclonal antibodies to TcdA and TcdB [18]. In the present study,
we deﬁne antigens which can underpin the large-scale production
of antibodies which potently neutralise TcdA and TcdB. We  also
show signiﬁcant differences between TcdA and TcdB with respect
to the protein regions which induce a toxin-neutralising immune
response.
In a previous study [18] and consistent with others [17], we
showed that a TcdB fragment representing the toxin’s effector (glu-
cosyltransferase) domain (residues 1–543) induced only a weak
toxin-neutralising response as measured by cell-based assays.
The present study focussed on various TcdB-derived recombi-
nant fragments derived from C-terminal and central regions of
TcdB. With all TcdB fragments assessed, their capacity to gen-
erate toxin-neutralising antibodies was  markedly enhanced by
limited treatment with formaldehyde. In the case of TcdB frag-
ments, short-term formaldehyde treatment led to enhancement in
toxin-neutralising potency of >100-fold for the majority of con-
structs. The mechanism of these enhancing effects is unclear, but
stabilisation of protein structure through intra-molecular cross-
linking (via methylene bridges) [37] is a possibility and such a
mechanism has been proposed from similar observations with
botulinum toxin fragments [38].
Consistent with other studies [23,27] immunising animals with
fragment TxB2 which contained the entire repeat region of TcdB,
generated antiserum with low toxin-neutralising titre. Inclusion
of TcdB domains from the central (translocation) region of the
toxin dramatically increased toxin-neutralising titres; in the case
of fragment TxB4, which consisted of the entire central (residues
767–1852) and repeat regions (residues 1852–2366), titres were
increased >120-fold. Immunisation of sheep with the central
domain fragment (TxBcen; residues 767–1852) elicited a potent
toxin-neutralising response conﬁrming the presence of neutralis-
ing epitopes within this region. While the neutralising titre afforded
by fragment TxB4 serum was  approximately 2–3-fold increased
compared to the central domain fragment TxBcen serum, the neu-
tralising titres of puriﬁed IgG fractions differed by <2-fold (Table 3)
which underlines the dominant role played by the TcdB central
region in eliciting neutralising immune response. Previous studies
on central domain fragments from TcdB reported derived antibod-
ies with poor neutralising titres [17]. However, as none of these
fragments represented the entire central domain, it is possible
that key toxin-neutralising epitopes were either absent or com-
promised.
Assessment of toxin-neutralising titres of serum produced using
TcdA-derived fragments revealed signiﬁcant differences in the
toxin regions which dominate the neutralising immune response
compared to TcdB. While the highest titres were obtained with
fragment TxA4 which consisted of both central and repeat regions,
fragment TxA2 which comprised solely the repeat region induced
a potent neutralising response and this is consistent with several
previous studies [17,23]. A fragment representing the TcdA cen-
tral region (TxAcen) gave neutralising titres markedly lower than
TxA2. Thus, in contrast to TcdB, the repeat region rather than the
central region appears to dominate the toxin-neutralising immune
response within the TcdA fragments assessed. That a C-terminally
truncated fragment, TxA4(tr), which contains only 4 of the 7 repeat
unit modules compared to the full-length fragment, gave a sig-
niﬁcantly reduced neutralising immune response (approx. 3-fold)
provides further evidence of the importance of this region. Previous
vaccine design strategies for combating CDI have largely been based
on antigens consisting of inactivated TcdA and TcdB holotoxins or
fragments derived from the toxins’ repeat regions [17,23,27]. Data
presented in this study suggest that for TcdB, the latter approach is
far from optimal as it omits key toxin-neutralising epitopes.
. / Vacc
w
b
p
c
a
n
a
i
s
a
e
T
c
d
T
w
i
f
e
g
t
m
D
H
o
I
A
t
t
a
m
p
n
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[M. Maynard-Smith et al
A further important consideration in the antigen design is
hether the generated antibodies provide protection against a
road range of C. difﬁcile isolates. Antibodies produced with TxA4
otently neutralised TcdA toxinotypes, 0, 3 and 5 with similar efﬁ-
acy. Potent neutralisation by TxB4 antibodies was  also observed
gainst various TcdB toxinotypes albeit with some reduction in
eutralising efﬁcacy: <3-fold against TcdB toxinotypes 3 and 5 and
pproximately a 7-fold reduction against a TcdB toxinotype 10. It
s notable that the latter unusual TcdB variant [39] showed least
equence homology compared to TcdB toxinotype 0 (85.7% overall
nd 88.1% within the central region).
In conclusion, the designed constructs TxA4 and TxB4 have sev-
ral properties which make them attractive as antigen candidates.
hey can be expressed in a soluble form in scalable, low cost E.
oli-based expression systems and were shown to induce the pro-
uction of antibodies which neutralise potently key toxinotypes of
cdA and TcdB. In addition, a mixture of the resulting antibodies
as shown to afford protection from severe CDI using the hamster
nfection model. Data presented in the study reveal signiﬁcant dif-
erences between TcdA and TcdB with respect to the domains which
voke a toxin-neutralising immune response. The described anti-
ens will support large-scale antibody production and so underpin
he development of an immunotherapeutic platfom for the treat-
ent of CDI.
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